Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

Impact · against what's priced in

The upcoming Phase 1b data for CTX310 is a potential catalyst for CRSP because the market currently discounts its cardiovascular pipeline. While the 40-million-patient addressable market is known, positive clinical results would validate a value driver the price currently declines.

CRSP+0.40

Challenges what's priced in

The price assumes

The cardiovascular and autoimmune pipeline data (CTX310's 50% lipid reductions...)